Synergistic use of glycomics and single‐molecule molecular inversion probes for identification of congenital disorders of glycosylation type‐1. Issue 4 (28th March 2022)

• Record Type: Journal Article
• Authors: Abu Bakar, Nurulamin; Ashikov, Angel; Brum, Jaime Moritz; Smeets, Roel; Kersten, Marjan; Huijben, Karin; Keng, Wee Teik; Speck‐Martins, Carlos Eduardo; de Carvalho, Daniel Rocha; de Rizzo, Isabela Maria Pinto Oliveira; de Mello, Walquiria Domingues; Heiner‐Fokkema, Rebecca; Gorman, Kathleen; Grunewald, Stephanie; Michelakakis, Helen; Moraitou, Marina; Martinelli, Diego; van Scherpenzeel, Monique; Janssen, Mirian; de Boer, Lonneke; van den Heuvel, Lambertus P.; Thiel, Christian; Lefeber, Dirk J.
• Is Part Of: Journal of inherited metabolic disease. Volume 45:Issue 4(2022)
• Page Start: 769
• Page End: 781
• Publication Date: 2022-03-28
• Subjects: CDG type 1 (CDG‐I) -- congenital disorders of glycosylation (CDG) -- diagnostics by mass spectrometry -- glycomics -- multi‐omics -- smMIPs; Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1002/jimd.12496
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: Congenital disorders of glycosylation type 1 (CDG‐I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms. The biochemical hallmark of CDG‐I is a partial absence of complete N‐glycans on transferrin. However, recent findings of a diagnostic N‐tetrasaccharide for ALG1‐CDG and increased high‐mannose N‐glycans for a few other CDG suggested the potential of glycan structural analysis for CDG‐I gene discovery. We analyzed the relative abundance of total plasma N‐glycans by high resolution quadrupole time‐of‐flight mass spectrometry in a large cohort of 111 CDG‐I patients with known ( n = 75) or unsolved ( n = 36) genetic cause. We designed single‐molecule molecular inversion probes (smMIPs) for sequencing of CDG‐I candidate genes on the basis of specific N‐glycan signatures. Glycomics profiling in patients with known defects revealed novel features such as the N‐tetrasaccharide in ALG2‐CDG patients and a novel fucosylated N ‐pentasaccharide as specific glycomarker for ALG1‐CDG. Moreover, group‐specific high‐mannose N‐glycan signatures were found in ALG3‐, ALG9‐, ALG11‐, ALG12‐, RFT1‐, SRD5A3‐, DOLK‐, DPM1‐, DPM3‐, MPDU1‐, ALG13‐CDG, and hereditary fructose intolerance. Further differential analysis revealed high‐mannose profiles, characteristic for ALG12‐ and ALG9‐CDG. Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG‐I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36). Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG‐I patient cohorts.